Gain Therapeutics, Inc. (GANX)

USD 1.54

(-8.33%)

Market Cap (In USD)

40.84 Million

Revenue (In USD)

55.18 Thousand

Net Income (In USD)

-22.26 Million

Avg. Volume

350.13 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.89-5.33
PE
-
EPS
-
Beta Value
0.336
ISIN
US36269B1052
CUSIP
36269B105
CIK
1819411
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Gene Mack M.B.A.
Employee Count
-
Website
https://www.gaintherapeutics.com
Ipo Date
2021-03-19
Details
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.